The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates. 

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

All-cause mortality after five years is much more likely if a TAVR patient presents with CAD, according to a new analysis published in JACC: Cardiovascular Interventions.

After finding success in Europe, the company is focused on gaining FDA approval for its Trilogy Heart Valve System and launching the device in the United States. 

Though removal of the affected CIED is typically the smartest treatment option—and one supported by specialty groups all over the world—a majority of patients keep living with the device, often resulting in hospitalization or even death.

Affera’s portfolio includes interventional solutions such as the Affera Prism-1 mapping and navigation platform, designed to help electrophysiologists diagnose heart rhythm issues, and the Sphere-9 cardiac ablation catheter.